Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel-Reference-Cited by-同舟云学术

Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel

Published:2010-02 Issue:1 Volume:10 Page:21-27
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cheson Bruce D.,Wendtner Clemens-Martin,Pieper Angelika,Dreyling Martin,Friedberg Jonathan,Hoelzer Dieter,Moreau Philippe,Gribben John,Knop Stefan,Montillo Marco,Rummel Mathias

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference35 articles.

1. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia;Knauf;J Clin Oncol,2009

2. Bendamustine in patients with rituximab refractory and alkylator-refractory, indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter single-agent study;Friedberg;J Clin Oncol,2008

3. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study;Kahl;Cancer,2009

4. Bendamustine: rebirth of an old drug;Cheson;J Clin Oncol,2009

5. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents;Leoni;Clin Cancer Res,2008

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients;Frontiers in Immunology;2023-12-01

2. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan;Cancer Chemotherapy and Pharmacology;2022-07

3. Evaluation of Volatility of Bendamustine Using Solid Phase Extraction-Type Extraction Device;CHROMATOGRAPHY;2022-06-20

4. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia;Journal of Clinical Oncology;2020-09-01

5. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study;Annals of Hematology;2019-07-08